BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 11389032)

  • 1. Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma.
    van Kemenade FJ; Raaphorst FM; Blokzijl T; Fieret E; Hamer KM; Satijn DP; Otte AP; Meijer CJ
    Blood; 2001 Jun; 97(12):3896-901. PubMed ID: 11389032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coexpression of BMI-1 and EZH2 polycomb group genes in Reed-Sternberg cells of Hodgkin's disease.
    Raaphorst FM; van Kemenade FJ; Blokzijl T; Fieret E; Hamer KM; Satijn DP; Otte AP; Meijer CJ
    Am J Pathol; 2000 Sep; 157(3):709-15. PubMed ID: 10980109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased expression of the EZH2 polycomb group gene in BMI-1-positive neoplastic cells during bronchial carcinogenesis.
    Breuer RH; Snijders PJ; Smit EF; Sutedja TG; Sewalt RG; Otte AP; van Kemenade FJ; Postmus PE; Meijer CJ; Raaphorst FM
    Neoplasia; 2004; 6(6):736-43. PubMed ID: 15720799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct BMI-1 and EZH2 expression patterns in thymocytes and mature T cells suggest a role for Polycomb genes in human T cell differentiation.
    Raaphorst FM; Otte AP; van Kemenade FJ; Blokzijl T; Fieret E; Hamer KM; Satijn DP; Meijer CJ
    J Immunol; 2001 May; 166(10):5925-34. PubMed ID: 11342607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In aggressive variants of non-Hodgkin lymphomas, Ezh2 is strongly expressed and polycomb repressive complex PRC1.4 dominates over PRC1.2.
    Abd Al Kader L; Oka T; Takata K; Sun X; Sato H; Murakami I; Toji T; Manabe A; Kimura H; Yoshino T
    Virchows Arch; 2013 Nov; 463(5):697-711. PubMed ID: 23948956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Site-specific expression of polycomb-group genes encoding the HPC-HPH/PRC1 complex in clinically defined primary nodal and cutaneous large B-cell lymphomas.
    Raaphorst FM; Vermeer M; Fieret E; Blokzijl T; Dukers D; Sewalt RG; Otte AP; Willemze R; Meijer CJ
    Am J Pathol; 2004 Feb; 164(2):533-42. PubMed ID: 14742259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma.
    Visser HP; Gunster MJ; Kluin-Nelemans HC; Manders EM; Raaphorst FM; Meijer CJ; Willemze R; Otte AP
    Br J Haematol; 2001 Mar; 112(4):950-8. PubMed ID: 11298590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer.
    Berezovska OP; Glinskii AB; Yang Z; Li XM; Hoffman RM; Glinsky GV
    Cell Cycle; 2006 Aug; 5(16):1886-901. PubMed ID: 16963837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene.
    Raaphorst FM; Meijer CJ; Fieret E; Blokzijl T; Mommers E; Buerger H; Packeisen J; Sewalt RA; Otte AP; van Diest PJ
    Neoplasia; 2003; 5(6):481-8. PubMed ID: 14965441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unique polycomb gene expression pattern in Hodgkin's lymphoma and Hodgkin's lymphoma-derived cell lines.
    Dukers DF; van Galen JC; Giroth C; Jansen P; Sewalt RG; Otte AP; Kluin-Nelemans HC; Meijer CJ; Raaphorst FM
    Am J Pathol; 2004 Mar; 164(3):873-81. PubMed ID: 14982841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cutting edge: polycomb gene expression patterns reflect distinct B cell differentiation stages in human germinal centers.
    Raaphorst FM; van Kemenade FJ; Fieret E; Hamer KM; Satijn DP; Otte AP; Meijer CJ
    J Immunol; 2000 Jan; 164(1):1-4. PubMed ID: 10604983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A transgenic mouse model demonstrating the oncogenic role of mutations in the polycomb-group gene EZH2 in lymphomagenesis.
    Berg T; Thoene S; Yap D; Wee T; Schoeler N; Rosten P; Lim E; Bilenky M; Mungall AJ; Oellerich T; Lee S; Lai CK; Umlandt P; Salmi A; Chang H; Yue L; Lai D; Cheng SW; Morin RD; Hirst M; Serve H; Marra MA; Morin GB; Gascoyne RD; Aparicio SA; Humphries RK
    Blood; 2014 Jun; 123(25):3914-24. PubMed ID: 24802772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features.
    van Leenders GJ; Dukers D; Hessels D; van den Kieboom SW; Hulsbergen CA; Witjes JA; Otte AP; Meijer CJ; Raaphorst FM
    Eur Urol; 2007 Aug; 52(2):455-63. PubMed ID: 17134822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polycomb protein EZH2 expression in diffuse large B-cell lymphoma is associated with better prognosis in patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone.
    Lee HJ; Shin DH; Kim KB; Shin N; Park WY; Lee JH; Choi KU; Kim JY; Lee CH; Sol MY
    Leuk Lymphoma; 2014 Sep; 55(9):2056-63. PubMed ID: 24304372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mel-18 acts as a tumor suppressor by repressing Bmi-1 expression and down-regulating Akt activity in breast cancer cells.
    Guo WJ; Zeng MS; Yadav A; Song LB; Guo BH; Band V; Dimri GP
    Cancer Res; 2007 Jun; 67(11):5083-9. PubMed ID: 17545584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance.
    Kikuchi J; Kinoshita I; Shimizu Y; Kikuchi E; Konishi J; Oizumi S; Kaga K; Matsuno Y; Nishimura M; Dosaka-Akita H
    Cancer; 2010 Jun; 116(12):3015-24. PubMed ID: 20564407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression changes in EZH2, but not in BMI-1, SIRT1, DNMT1 or DNMT3B are associated with DNA methylation changes in prostate cancer.
    Hoffmann MJ; Engers R; Florl AR; Otte AP; Muller M; Schulz WA
    Cancer Biol Ther; 2007 Sep; 6(9):1403-12. PubMed ID: 18637271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential expression of enhancer of zeste homolog 2 (EZH2) protein in small cell and aggressive B-cell non-Hodgkin lymphomas and differential regulation of EZH2 expression by p-ERK1/2 and MYC in aggressive B-cell lymphomas.
    Tian X; Pelton A; Shahsafaei A; Dorfman DM
    Mod Pathol; 2016 Sep; 29(9):1050-7. PubMed ID: 27282353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A marginal zone pattern may be found in different varieties of non-Hodgkin's lymphoma: the morphology and immunohistology of splenic involvement by B-cell lymphomas simulating splenic marginal zone lymphoma.
    Piris MA; Mollejo M; Campo E; Menárguez J; Flores T; Isaacson PG
    Histopathology; 1998 Sep; 33(3):230-9. PubMed ID: 9777389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of serine 194-phosphorylated Fas-associated death domain protein correlates with proliferation in B-cell non-Hodgkin lymphomas.
    Drakos E; Leventaki V; Atsaves V; Schlette EJ; Lin P; Vega F; Miranda RN; Claret FX; Medeiros LJ; Rassidakis GZ
    Hum Pathol; 2011 Aug; 42(8):1117-24. PubMed ID: 21315423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.